Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
R613090-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $271.90 | |
R613090-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $948.90 |
Synonyms | (s)-5-ethyl-4-methyl-n-(4-(morpholin-2-yl)phenyl)-1h-pyrazole-3-carboxamide | 5-Ethyl-4-methyl-N-{4-[(2S)-morpholin-2-yl]phenyl}-1H-pyrazole-3-carboxamide | 5-Ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide | DTXSID901336976 | 1 |
---|---|
Specifications & Purity | Moligand™ |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of TA 1 receptor |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 5-ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide |
---|---|
INCHI | InChI=1S/C17H22N4O2/c1-3-14-11(2)16(21-20-14)17(22)19-13-6-4-12(5-7-13)15-10-18-8-9-23-15/h4-7,15,18H,3,8-10H2,1-2H3,(H,19,22)(H,20,21)/t15-/m1/s1 |
InChi Key | XHHXGKRFUPEPFM-OAHLLOKOSA-N |
Canonical SMILES | CCC1=C(C(=NN1)C(=O)NC2=CC=C(C=C2)C3CNCCO3)C |
Isomeric SMILES | CCC1=C(C(=NN1)C(=O)NC2=CC=C(C=C2)[C@H]3CNCCO3)C |
Alternate CAS | 2133417-13-5 |
PubChem CID | 130429734 |
PubChem CID | 130429734 |
---|---|
ChEMBL Ligand | CHEMBL4594376 |
CAS Registry No. | 2133417-13-5 |
Enter Lot Number to search for COA:
1. Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. (2021) Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.. Int J Mol Sci, 22 (24): (1755-70). [PMID:34947997] [10.1021/op500134e] |
2. Sparacino G, Verdolini N, Vieta E, Pacchiarotti I. (2022) Existing and emerging pharmacological approaches to the treatment of mania: A critical overview.. Transl Psychiatry, 12 (1): (169). [PMID:35461339] [10.1021/op500134e] |
3. Kantrowitz JT. (2021) Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions.. CNS Drugs, 35 (11): (1153-1161). [PMID:34655036] [10.1021/op500134e] |
4. Kane JM. (2022) A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.. J Clin Psychopharmacol, 42 (5 Suppl 1): (S1-S13). [PMID:36099402] [10.1021/op500134e] |